Condensed Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net income (loss)	$ 443,277	$ (504,571)
Adjustments to reconcile net income (loss) net cash provided by operating activities:
Depreciation expense	13,114	14,482
Amortization of patents	58,360	57,097
Amortization of debt discount	0	3,065
Common stock and options for compensation, consulting, and vendor services	512,846	281,648
Loss on sale/disposal of equipment	0	1,604
Accrued interest expense on notes payable	0	0
Bad debt reversal	(295,488)	(140,293)
Loss on Earning on Medical Joint Venture	259,291	124,179
Changes in operating assets and liabilities:
(Increase) Decrease in accounts receivable	(309,424)	596,931
(Increase) Decrease in inventories	(235,998)	119,839
Decrease to advance to contracts	273,885	315,736
Decrease to prepaid expenses and other current assets	137,117	168,237
(Increase) Decrease in other assets	(5,600)	20,503
Decrease in accounts payable	(530,190)	(1,326,398)
Increase in accrued expenses	120,889	320,733
Net cash provided by operating activities	442,079	52,792
Cash flows from investing activities:
Investment in Milestone Education LLC	(50,000)	0
Investment in Milestone Medical, Inc.	(259,291)	0
Purchases of property and equipment	(3,111)	(4,061)
Payment for patents rights	(17,690)	(21,529)
Net cash used in investing activities	(330,092)	(25,590)
Cash flows from financing activities:
Proceeds from exercise of stock options	29,600	0
Proceeds from the sale of common stock	50,000	150,000
Proceeds from related party loan	50,000	0
Repayment of related party loan	(5,000)	0
Net cash provided by financing activities	124,600	150,000
NET INCREASE IN CASH AND CASH EQUIVALENTS	236,587	177,202
Cash and cash equivalents at beginning of period	165,249	96,324
Cash and cash equivalents at end of period	401,836	273,526
Supplemental disclosure of cash flow information
Shares issued to directors for the exercise of stock options	29,600	0
Shares issued to directors for compensation	45,000	45,000
Shares issued for conversion of notes payable and accrued interest	860,081	0
Shares issued to employees in lieu of cash compensation	$ 35,625	$ 31,250